BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Prozac
,
rs2300478
,
PDX1
,
Angiogenesis
,
Breast Cancer
,
Lung
,
Amniocentesis
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
ose level</a>
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for ose level</a>
Explore Curated Studies Results
Literature
Most Relevant Literature
Estimation of time to progression and post progression survival using joint modeling of summary leve…
The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine …
Symptomatic os trigonum in national level javelin thrower: a case report.
An obscure case of using apixaban anti-Xa levels in a morbidly obese patient who was nil per os with…
Retracted os peroneum with partial integrity of the peroneus longus tendon.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
A Study Called NATION-OS to Learn About the Link Between N-terminal proBNP (NT-proBNP) Levels and Me…
Variability of Definitions for Survival Endpoints and Surrogate Properties for OS: a Meta-analysis
Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ